How Antibodies Work: Structure, Function, and Types

Antibody Structure

Every antibody molecule is built from four polypeptide chains: two identical heavy chains and two identical light chains, held together by disulfide bonds in a characteristic Y shape. The two arms of the Y contain the antigen-binding sites, while the stem of the Y (called the Fc region) determines the antibody's effector functions, meaning how it interacts with other components of the immune system after binding its target.

Each chain has a variable region at the amino-terminal end and a constant region at the carboxy-terminal end. The variable regions of the heavy and light chains together form the antigen-binding site, also called the paratope. Within each variable region, there are three short segments of especially high sequence variability called complementarity-determining regions (CDRs), which make direct physical contact with the antigen. The CDRs form loops that project from a framework of more conserved beta-sheet structures, creating a binding surface that can recognize epitopes of many different shapes: small molecules, peptide sequences, carbohydrate chains, and even three-dimensional protein surfaces.

The Fc region of the antibody interacts with Fc receptors on immune cells and with complement proteins. Different antibody classes have structurally different Fc regions, which is why each class triggers different effector mechanisms. The hinge region between the arms and the stem provides flexibility, allowing the two antigen-binding sites to adjust their spacing and bind to antigens separated by varying distances on a pathogen surface.

The Five Classes of Antibodies

Humans produce five major classes (isotypes) of antibodies, designated by the type of heavy chain constant region they contain. Each class has a distinct structure, distribution, and set of biological functions.

IgG is the most abundant antibody in the blood and extracellular fluid, accounting for roughly 75 percent of total serum immunoglobulins. It is the dominant antibody of secondary immune responses and is produced in large quantities after vaccination or recovery from infection. IgG is the only antibody class that crosses the placenta, providing passive immunity to the developing fetus and newborn during the first months of life. It activates complement, promotes phagocytosis through opsonization, and mediates antibody-dependent cellular cytotoxicity (ADCC). There are four IgG subclasses (IgG1 through IgG4), each with slightly different Fc region properties and effector functions.

IgA is the principal antibody at mucosal surfaces, including the linings of the respiratory tract, gastrointestinal tract, and urogenital tract. Secretory IgA exists as a dimer, two IgA molecules joined by a J chain and wrapped in a secretory component that protects it from enzymatic degradation in the harsh mucosal environment. IgA is the most abundantly produced antibody in the human body overall, with an estimated 3 to 5 grams secreted daily into mucosal fluids. Its primary function is neutralization: it binds to pathogens and toxins in the mucus layer before they can reach and penetrate the epithelial barrier. Breast milk is rich in secretory IgA, providing mucosal immunity to nursing infants.

IgM is the first antibody class produced during a primary immune response and is also the first antibody expressed on the surface of developing B cells. In its secreted form, IgM is a pentamer, five Y-shaped units joined by disulfide bonds and a J chain, giving it 10 antigen-binding sites. This multivalent structure makes IgM extremely efficient at cross-linking antigens and activating the complement cascade, even though each individual binding site has relatively low affinity compared to IgG. IgM is largely confined to the bloodstream because its large size prevents it from crossing easily into tissues.

IgE is present at extremely low concentrations in the blood, typically less than 0.001 percent of total serum immunoglobulins. Despite its scarcity, IgE plays an outsized role in two contexts: defense against parasitic worms and allergic disease. IgE binds with very high affinity to Fc epsilon receptors on mast cells and basophils. When an allergen or parasite antigen cross-links surface-bound IgE molecules, the mast cell degranulates, releasing histamine, proteases, and lipid mediators that produce the symptoms of allergic reactions or that damage parasites. In regions where parasitic worms are common, IgE levels are naturally elevated; in industrialized nations where parasite exposure is rare, IgE is primarily associated with allergies and asthma.

IgD is found mainly on the surface of naive B cells, where it functions alongside IgM as an antigen receptor before the cell has been activated. Secreted IgD is present at very low levels in the blood, and its biological functions remain the least understood of any antibody class. Recent research suggests that IgD may play roles in mucosal immunity, basophil activation, and immune surveillance of the upper respiratory tract, but these functions are still being characterized.

How Antibodies Defend the Body

Antibodies protect against infection through four main mechanisms, each exploiting the antibody's ability to bind specifically to foreign antigens.

Neutralization is the simplest mechanism. When an antibody binds to a critical site on a virus or toxin, it physically blocks the pathogen from attaching to its host cell receptor. Neutralizing antibodies against the SARS-CoV-2 spike protein, for example, bind to the receptor-binding domain and prevent the virus from docking to ACE2 on human cells. Neutralization does not destroy the pathogen but renders it harmless, and the neutralized complex is eventually cleared by phagocytes.

Opsonization coats the pathogen surface with antibody molecules, making it dramatically easier for phagocytes to engulf and destroy it. Macrophages and neutrophils carry Fc receptors that bind to the Fc region of antibodies coating a pathogen. This interaction triggers phagocytosis and activates the phagocyte's killing mechanisms. Opsonization increases phagocytic efficiency by 100-fold or more compared to uncoated targets.

Complement activation occurs when IgG or IgM molecules bound to a pathogen surface recruit C1q, the first component of the classical complement pathway. This triggers an enzymatic cascade that generates C3b (an opsonin), C3a and C5a (inflammatory mediators that recruit immune cells), and the membrane attack complex (MAC), a ring of proteins that inserts into the pathogen's membrane and creates a pore, causing osmotic lysis. The complement cascade amplifies the initial antibody signal enormously: a single antibody-antigen complex can trigger the deposition of hundreds of C3b molecules on the pathogen surface.

Antibody-dependent cellular cytotoxicity (ADCC) allows NK cells and other immune cells to kill antibody-coated target cells. NK cells express the Fc receptor CD16 (FcgammaRIII), which binds to IgG molecules on the target surface. This binding activates the NK cell, triggering the release of perforin and granzymes that induce apoptosis in the target cell. ADCC is an important mechanism for clearing virus-infected cells and tumor cells, and it is a major mode of action for several therapeutic monoclonal antibodies used in cancer treatment.

Generating Antibody Diversity

The human genome contains fewer than 25,000 genes, yet the immune system can produce over 10^11 distinct antibody specificities. This enormous diversity is generated through V(D)J recombination, a process of programmed DNA rearrangement that occurs during B cell development in the bone marrow.

The genes encoding the variable regions of antibody heavy and light chains are organized into segments: variable (V), diversity (D, heavy chain only), and joining (J) segments. During B cell development, the RAG1 and RAG2 enzymes catalyze the random selection and joining of one V, one D (for heavy chains), and one J segment from the available pools. The human heavy chain locus contains approximately 40 functional V segments, 23 D segments, and 6 J segments; the kappa light chain locus contains approximately 34 V segments and 5 J segments. The combinatorial diversity from random segment selection generates thousands of different heavy chain and light chain variable regions.

Additional diversity is introduced at the junctions between gene segments during recombination. The enzyme terminal deoxynucleotidyl transferase (TdT) adds random nucleotides at the V-D and D-J junctions, a process called junctional diversity that increases the repertoire by orders of magnitude. The random pairing of different heavy and light chains further multiplies diversity. Together, these mechanisms generate the estimated 10^11 unique antibody specificities.

After initial activation, B cells undergo somatic hypermutation in the germinal centers of lymph nodes. The enzyme activation-induced cytidine deaminase (AID) introduces point mutations into the variable region genes at a rate roughly a million times higher than the normal mutation rate. B cells whose mutated antibodies bind their target antigen with higher affinity receive survival signals from follicular helper T cells and are selected to proliferate; those with lower affinity die. This Darwinian process, called affinity maturation, produces antibodies of progressively higher quality over the course of an immune response. It is the reason why the antibodies produced weeks after an infection or vaccination are far more effective than those produced in the first few days.

Monoclonal Antibodies in Medicine

The ability to produce identical copies of a single antibody specificity, called monoclonal antibodies, has transformed both research and clinical medicine. The technique was developed by Georges Kohler and Cesar Milstein in 1975, for which they received the Nobel Prize. Modern monoclonal antibodies are engineered for therapeutic use against cancer (trastuzumab, rituximab, pembrolizumab), autoimmune diseases (adalimumab, infliximab), and infectious diseases (casirivimab for COVID-19).

Monoclonal antibodies now represent one of the fastest-growing segments of the pharmaceutical industry, with global sales exceeding $200 billion annually. They can be engineered with modified Fc regions to enhance or suppress specific effector functions, conjugated to cytotoxic drugs for targeted delivery to cancer cells (antibody-drug conjugates), or formatted as bispecific antibodies that bind two different targets simultaneously. The versatility of antibody engineering, combined with the immune system's natural ability to generate high-affinity binders, has made monoclonal antibodies among the most successful class of therapeutic molecules ever developed.